Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Ensysce Biosciences, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 15 | 18 | +3 |
| Shares | 487.0K | 904.7K | +417.7K (+85.8%) |
| Value | $261.5K | $261.1K | −$430 (−0.2%) |
New holders (5)
Institutions that held Ensysce Biosciences, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 54,429 | $15.0K | 0.00% |
| Susquehanna International Group, LLP | 34,280 | $9.94K | 0.00% |
| Two Sigma Securities, LLC | 12,953 | $3.76K | 0.00% |
| Barclays PLC | 1,440 | $418 | 0.00% |
| Clear Street Group Inc. | 1 | $0 | 0.00% |
Sold out (2)
Institutions that held Ensysce Biosciences, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Vanguard Fiduciary Trust Co | 23,854 | $12.9K |
| UBS Group AG | 8,791 | $4.73K |